An evaluation of the functions of the 22-kilodalton (kDa), the 20-kDa, and the N-terminal polypeptide forms of human growth hormone using transgenic mice - PubMed (original) (raw)
An evaluation of the functions of the 22-kilodalton (kDa), the 20-kDa, and the N-terminal polypeptide forms of human growth hormone using transgenic mice
T A Stewart et al. Endocrinology. 1992 Jan.
Abstract
Multiple peptide hormones can be derived from the single human GH gene. In addition to the full-length 191-amino acid 22-kilodalton (kDa) form, a 20-kDa variant can be produced by alternative splicing, and a 5-kDa variant can be produced by posttranslational cleavage. To more fully appreciate the physiological roles of these proteins, we have made a comparison of transgenic mice that constitutively overexpress one or another of these variants. We have found that both the 22-kDa and the 20-kDa forms of human GH stimulate linear growth and liver hypertrophy. The increase in linear growth in 22-kDa transgenic mice does not, however, correlate with an increase in circulating IGF-I; rather, the increase in IGF-I that does finally occur correlates with marked liver pathology. Both groups of mice also develop glomerulosclerosis and suffer from hyperinsulinemia. Although there are histologically obvious lesions in the livers of both the 22-kDa and the 20-kDa transgenic mice, only the former exhibit hyperalbuminemia and hypercholesterolemia. Both forms of GH lead to anemia, which is normocytic in the 20-kDa transgenic mice and macrocytic in the 22-kDa transgenic mice. Despite the presence of high levels of the 5-kDa N-terminal form of human GH, the transgenic mice that express this protein are indistinguishable from their nontransgenic littermates.
Similar articles
- Growth inhibition in giant growth hormone transgenic mice by overexpression of insulin-like growth factor-binding protein-2.
Hoeflich A, Nedbal S, Blum WF, Erhard M, Lahm H, Brem G, Kolb HJ, Wanke R, Wolf E. Hoeflich A, et al. Endocrinology. 2001 May;142(5):1889-98. doi: 10.1210/endo.142.5.8149. Endocrinology. 2001. PMID: 11316754 - Expression of insulin-like growth factor I stimulates normal somatic growth in growth hormone-deficient transgenic mice.
Behringer RR, Lewin TM, Quaife CJ, Palmiter RD, Brinster RL, D'Ercole AJ. Behringer RR, et al. Endocrinology. 1990 Sep;127(3):1033-40. doi: 10.1210/endo-127-3-1033. Endocrinology. 1990. PMID: 2387246 - Growth hormone transgenes regulate the expression of sex-specific isoforms of 3 beta-hydroxysteroid dehydrogenase/delta 5-->4-isomerase in mouse liver and gonads.
Keeney DS, Murry BA, Bartke A, Wagner TE, Mason JI. Keeney DS, et al. Endocrinology. 1993 Sep;133(3):1131-8. doi: 10.1210/endo.133.3.8365357. Endocrinology. 1993. PMID: 8365357 - Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice.
Chen NY, Chen WY, Bellush L, Yang CW, Striker LJ, Striker GE, Kopchick JJ. Chen NY, et al. Endocrinology. 1995 Feb;136(2):660-7. doi: 10.1210/endo.136.2.7835300. Endocrinology. 1995. PMID: 7835300 - A transgenic model to determine the physiological role of liver-derived insulin-like growth factor I.
Sjögren K, Jansson JO, Isaksson OG, Ohlsson C. Sjögren K, et al. Minerva Endocrinol. 2002 Dec;27(4):299-311. Minerva Endocrinol. 2002. PMID: 12511852 Review.
Cited by
- Extensive phenotypic characterization of a new transgenic mouse reveals pleiotropic perturbations in physiology due to mesenchymal hGH minigene expression.
Kaklamanos A, Rozman J, Roulis M, Karagianni N, Armaka M, Wu M, Brachthäuser L, Calzada-Wack J, Horsch M, Beckers J, Rathkolb B, Adler T, Neff F, Wolf E, Gailus-Durner V, Fuchs H, de Angelis MH, Kollias G. Kaklamanos A, et al. Sci Rep. 2017 May 25;7(1):2397. doi: 10.1038/s41598-017-02581-8. Sci Rep. 2017. PMID: 28546545 Free PMC article. - Molecular heterogeneity of human GH: from basic research to clinical implications.
Boguszewski CL. Boguszewski CL. J Endocrinol Invest. 2003 Mar;26(3):274-88. doi: 10.1007/BF03345170. J Endocrinol Invest. 2003. PMID: 12809181 Review. No abstract available. - Disruption of exon definition produces a dominant-negative growth hormone isoform that causes somatotroph death and IGHD II.
Ryther RC, McGuinness LM, Phillips JA 3rd, Moseley CT, Magoulas CB, Robinson IC, Patton JG. Ryther RC, et al. Hum Genet. 2003 Jul;113(2):140-8. doi: 10.1007/s00439-003-0949-x. Epub 2003 Apr 29. Hum Genet. 2003. PMID: 12720086 - A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.
Nicholes K, Guillet S, Tomlinson E, Hillan K, Wright B, Frantz GD, Pham TA, Dillard-Telm L, Tsai SP, Stephan JP, Stinson J, Stewart T, French DM. Nicholes K, et al. Am J Pathol. 2002 Jun;160(6):2295-307. doi: 10.1016/S0002-9440(10)61177-7. Am J Pathol. 2002. PMID: 12057932 Free PMC article. - Transgenic studies with a keratin promoter-driven growth hormone transgene: prospects for gene therapy.
Wang X, Zinkel S, Polonsky K, Fuchs E. Wang X, et al. Proc Natl Acad Sci U S A. 1997 Jan 7;94(1):219-26. doi: 10.1073/pnas.94.1.219. Proc Natl Acad Sci U S A. 1997. PMID: 8990189 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources